Recurrent Multiple Myeloma clinical trials

Explore recruiting recurrent multiple myeloma clinical trials.

Recruiting recurrent multiple myeloma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Recurrent Multiple Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Teclistamab plus autologous lymphocytes infusion for the treatment of relapsed/refractory Multiple Myeloma (TALIM). MM0125

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Recurrent Multiple Myeloma trials by city

Recurrent Multiple Myeloma clinical trials

Recruiting recurrent multiple myeloma studies right now

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

CAR-T in Relapsed/Refractory Multiple Myeloma

Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Also recruiting in Europe

Teclistamab plus autologous lymphocytes infusion for the treatment of relapsed/refractory Multiple Myeloma (TALIM). MM0125

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma

Recurrent Multiple Myeloma trials by city

Other conditions